Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumour vasculature

In the past three decades, two very important findings regarding tumour vasculature have been made. Firstly, it has been known a solid turnout has to establish an adequate blood supply to grow beyond a critical mass. Secondly, it has been proven that the turnout vasculature is relatively more aberrant, dynamic and permeable than healthy host tissue. This review discusses the potential of delivering therapeutic nucleic acids to turnout vasculature using cationic liposomes, vehicles recently demonstrated to be selectively delivered to tumour vasculature. (C) 2003 Elsevier B.V. All rights reserved.